STOK - Stoke Therapeutics, Inc.

QQQ $ 608.45 $ 0.46 (0.08 %)

DIA $ 471.65 $ -2.94 (-0.62 %)

SPY $ 671.62 $ -0.11 (-0.02 %)

TLT $ 88.93 $ -0.51 (-0.57 %)

GLD $ 375.82 $ -6.91 (-1.8 %)

Previous Close

$ 26.51

Open

$ 25.89

Bid

$ 26.71 x 5

Ask

$ 26.75 x 171

Day's Range

$ 25.85 - $ 27.88

52 Week Range

$ 5.35 - $ 38.69

Volume

1,013,819

Average Volume

Market Cap

1.51B

Beta (5Y Monthly)

$ 1.53

PE Ratio (TTM)

$ 37.33

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	09-30-2025	10-Q
2	08-12-2025	06-30-2025	10-Q
3	05-13-2025	03-31-2025	10-Q
4	03-18-2025	12-31-2024	10-K
5	11-05-2024	09-30-2024	10-Q
6	08-07-2024	06-30-2024	10-Q
7	05-06-2024	03-31-2024	10-Q
8	03-25-2024	12-31-2023	10-K
9	11-07-2023	09-30-2023	10-Q
10	08-07-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	03-06-2023	12-31-2022	10-K
13	11-14-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-10-2022	03-31-2022	10-Q
16	03-10-2022	12-31-2021	10-K
17	11-08-2021	09-30-2021	10-Q
18	08-10-2021	06-30-2021	10-Q
19	05-10-2021	03-31-2021	10-Q
20	03-09-2021	12-31-2020	10-K
21	11-12-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-15-2020	03-31-2020	10-Q
24	03-23-2020	12-31-2019	10-K
25	11-12-2019	09-30-2019	10-Q
26	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Canaccord Genuity Maintains Buy on Stoke T...
11/05/2025 18:31:28

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target ...

Wedbush Maintains Outperform on Stoke Ther...
11/05/2025 14:23:27

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $2...

6 Analysts Have This To Say About Stoke Th...
11/05/2025 11:45:33

BTIG Reiterates Buy on Stoke Therapeutics,...
11/05/2025 10:15:05

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.

12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

Stoke Therapeutics Q3 EPS $(0.65) Misses $...
11/04/2025 21:02:41

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of ...

Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

Examining the Future: Stoke Therapeutics's...
11/03/2025 20:02:44

JP Morgan Maintains Neutral on Stoke Thera...
11/03/2025 15:53:14

JP Morgan analyst Jessica Fye maintains Stoke Therapeutics (NASDAQ:STOK) with a Neutral and raises the price target from $15...

Stoke Therapeutics Unveils Two-Year Data O...
10/20/2025 11:36:16

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bod...

What 4 Analyst Ratings Have To Say About S...
10/10/2025 22:01:27

Needham Maintains Buy on Stoke Therapeutic...
10/10/2025 10:22:26

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $22 t...

Biogen And Stoke Announce Phase 3 Zorevune...
10/09/2025 20:32:46

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

Stoke Therapeutics Names Ian F. Smith CEO
10/06/2025 11:36:29

Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Exe...

Reported Earlier, Biogen And Stoke Highlig...
09/03/2025 06:55:31

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Reported Earlier: Biogen And Stoke Therape...
09/02/2025 13:56:46

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Biogen And Stoke Therapeutics Announced Pr...
08/25/2025 11:10:57

Where Stoke Therapeutics Stands With Analysts
08/13/2025 20:01:40

Chardan Capital Maintains Buy on Stoke The...
08/13/2025 16:05:17

Chardan Capital analyst Rudy Li maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $24 price target.

Wedbush Maintains Outperform on Stoke Ther...
08/13/2025 14:30:48

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $1...